<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04012892</url>
  </required_header>
  <id_info>
    <org_study_id>HEM-NHL001-CART</org_study_id>
    <nct_id>NCT04012892</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, open label, phase I clinical trial to evaluate the safety and
      feasibility of CD19CAR-T in treatment of relapsed / refractory non-hodgkin lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recovery rate of patients being treated with CD19CAR-T</measure>
    <time_frame>6 months</time_frame>
    <description>the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapsed Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5Ã—10^4 cells/kg in 36-96 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CD19 CART</intervention_name>
    <description>CD19 CART</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis with Relapsed or refractory Non Hodgkin Lymphoma with CD19 positive

          2. Age 18 to 65 years old, both male and female;

          3. Is expected to survive more than 12 weeks;

          4. Physical condition is good: 0-1 score ECOG score;

          5. No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the
             body;

          6. Into groups to participate in voluntarily, good adherence, can cooperate test
             observation, childbearing age women must be 7 days before starting treatment expert
             pregnancy test and the results were negative, and signed a written informed consent
             form.

        Exclusion Criteria:

          1. Organ failure, such as heart: Class III and IV; liver: to Child grading of liver
             function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe
             respiratory failure; brain: disorder of consciousness;

          2. Existing serious acute infection, uncontrollable, or have fester sex and chronic
             infection, wound in delay no more;

          3. Pregnancy and lactation women;

          4. Patients who have participated in other clinical trials or other clinical trials in
             the past 30 days;

          5. The Investigator believe the patients should not participate in this experiment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lixing Wang, MD</last_name>
    <phone>86-0755-21839178</phone>
    <email>wanglixin1991@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen University General Hospital</name>
      <address>
        <city>Shenzhen</city>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lixing Wang, M.D.</last_name>
      <phone>86-0755-21839178</phone>
      <email>wanglixin1991@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Li Yu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lixing Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 7, 2019</last_update_submitted>
  <last_update_submitted_qc>July 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Li Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

